Search results
The Beckhams’ Fortune Rises, Pinault Lost 1.9 Billion Pounds, Sunday Times Rich List 2024 Shows
WWD via Yahoo Finance· 4 days ago(L) Mike Ashley Controversial retail magnate...by 41 million pounds to 3.799 billion pounds, ranking...
European Midday Briefing:
Morningstar· 6 days agoMeanwhile, the latest European Commission forecasts provide a gloomy fiscal picture, with expectations of a higher deficit for the eurozone, including for major countries ...
3 Tobacco Stocks Worth Watching Amid Industry Challenges
Zacks via Yahoo Finance· 4 days agoThe Zacks Tobacco industry companies have been grappling with soft cigarette volume and elevated...
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Market Exclusive· 2 days agoThe company’s CEO, Joseph Tucker, highlighted significant interest from strategic pharmaceutical partners for Enveric’s new drug candidates targeting mental ...
Chinese biotech crackdown would reset U.S. drug development
Axios· 6 days agoLawmakers in the House of Representatives on Wednesday are expected to set in motion a massive reordering of how U.S. pharmaceuticals are developed and made, by advancing a contracting ban on ...
Harrow (NASDAQ:HROW) Price Target Raised to $26.00
ETF DAILY NEWS· 3 days agoHarrow (NASDAQ:HROW – Free Report) had its price target lifted by Craig Hallum from $24.00 to $26.00 in a research report sent to investors on Wednesday, Benzinga reports.
Bipartisan scrutiny of health care mergers
Politico· 9 hours agoThe legislation has “major implications for health care,” Kirk Nahra, co-chair of law firm WilmerHale’s artificial intelligence practice, told Pulse. “We know the need to ...
Lingering Rate Uncertainty May Lead To Choppy Trading On Wall Street
RTT News· 10 hours agoThe major U.S. index futures are currently pointing to a roughly flat open on Tuesday, with stocks likely to show a lack of direction following the mixed performance seen ...
Amgen shares hold as FDA approves Imdelltra ahead of schedule By Investing.com
Investing.com· 4 days agoThe...'s decision came approximately one month prior to the anticipated Prescription Drug User Fee...
Guggenheim downgrades Bolt Biotherapeutics stock amid leading drug halt By Investing.com
Investing.com· 7 days ago(NASDAQ:BOLT), moving its rating from Buy to Neutral. The change in rating follows the company's...
